Clinical trial
Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study
NCT02480465 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- March 31, 2017
- Enrollment
- 248 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.